AUG 31, 2017 03:10 PM PDT

Ecstasy Given Green Light in PTSD Trial

WRITTEN BY: Xuan Pham

Image credit: Wikipedia.org

The FDA has been making quite a few historic decisions as of late, including the approval of the first gene therapy for the treatment of leukemia. In addition to that, the agency also granted a “Breakthrough Therapy Designation” status for an unlikely compound, MDMA, in the treatment of post-traumatic stress disorder (PTSD). As MDMA is the active ingredient in the recreational drug ecstasy, the decision to move forward with this designation marks a huge milestone for what proponents call a psychotherapy agent.

Post-traumatic stress disorder (PTSD) affects millions of people, but the disorder is notoriously difficult to treat. Even with our best treatment efforts, researchers say a significant portion of patients are still left behind.

Known on the street as “E,” “Molly,” and “millennial aspirin,” MDMA (3,4-Methylenedioxymethamphetamine) is a popular recreational psychedelic drug. The compound acts on the amygdala to induce feelings of euphoria, empathy, and otherwise heightened emotions.

Heavy abuse of the drug – leading to addiction, memory issues, paranoia, and other adverse symptoms – led the FDA to classify it as a Schedule 1 substance and its eventual ban. However, many researchers saw potential in MDMA as a psychotherapy drug, precisely because of how it affects the brain.

In a few early stage clinical trial of MDMA, patients reported working through their trauma in ways that could not be replicated with conventional treatments. One study found a 56 percent decrease in the severity of their PTSD symptoms with the use of MDMA. This shift led more than two-thirds of the patients to free themselves from the diagnosis of PTSD – a remarkable outcome considering the ineffectiveness rate of current therapies. Furthermore, the results seem to have a lasting effect, even after the drug was discontinued.

“The body of evidence that shows MDMA works is so strong and so encouraging,” said Rick Doblin, the founder and executive director of Multidisciplinary Association for Psychedelic Studies (MAPS), which is sponsoring the current Phase III clinical trial, involving over 200 participants.

The FDA usually reserves this designation for drugs that can “treat a serious or life threatening disease or condition.”

"By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD," according to the MAPS statement.

With this FDA nod, the MAPS association plans to move forward with a Phase 3 clinical trial in 2018 that will focus on “MDMA-assisted psychotherapy.” The success of the third phase of clinical trials is a tremendous milestone before going to market. It is also in this phase that many drug trials fail. However, if successful, MDMA could be on the fast track for approval as a PTSD psychotherapy drug by as early as 2021.

Of note, researchers underscore that the trial is to expand the psychedelic’s medicinal uses, not its recreational potential. So to people who doubt the safety of legal ecstasy, Doblin says: “This is never going to be a take-home drug. It’ll only be prescribed by doctors with special training, for people with specific conditions.”

Additional sources: MAPSLive Science

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 25, 2018
Clinical & Molecular DX
APR 25, 2018
Why is dementia going unnoticed in hospitals?
A study in the UK showed that while the rate of diagnosis for dementia is improving, more than a third of all dementia patients still go undiagnosed. The n...
APR 26, 2018
Cardiology
APR 26, 2018
New Gene Linked to Human Aortic Aneurysms
Using a web tool called GeneMatcher, scientists from Baylor College of Medicine studying defective copies of the ari-1 gene were matched up with scientists...
MAY 30, 2018
Cell & Molecular Biology
MAY 30, 2018
Diagnosing Deadly Kidney Cancers Sooner
Researchers have found that deadly kidney cancers can be identified by assessing their evolutionary path, which is different for distinct types....
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t...
JUN 08, 2018
Clinical & Molecular DX
JUN 08, 2018
Early Detection of Tooth Decay from Bacterial Invasion
We all get cavities, but have we ever thought much about the biology of the process? From the Akson Russian Science Communication Association, scientists i...
AUG 11, 2018
Microbiology
AUG 11, 2018
A Microbrewery can Help us Monitor Radiation Exposure
This wearable technology is very sensitive, and can be used by workers that are at risk of radiation exposure....
Loading Comments...